Patient Engagement

Designing and managing clinical outcome assessments on an international basis is more than a translation task. It requires the more discrete practice of linguistic validation, writes Dana Weiss.

DIA’s global chief executive talks with Pharm Exec about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its benefits in everyday practice.

Outlining a real-world example in which building and operationalizing a patient- and customer-centric commercialization strategy drove a successful launch from a “standing start.”

China's nurse educator program aims to improve quality of care and make life simpler for physicians handling high patient load. Sebastian Bather reports.

From AI to Alexa, experts in specialty pharma ponder the possibilities for high tech and the patient journey.

Addressing adherence with c-suite sponsorship and at scale has the capacity increase revenue, improve patient outcomes and lower health care costs, writes Tom Kottler.

The pharmaceutical industry needs to be paying more attention to consumer purchase habits.

Albert Thigpen, president and chief operating officer of CastiaRx, talks about how pharmaceuticals companies could be using devices such as Amazon’s Alexa to help improve patient adherence and the overall patient journey.His remarks come after a seminar at Asembia’s Specialty Pharmacy Summit in Las Vegas. 

With digitalization enabling patient engagement with their own health experience more than ever before, two critical elements will steer pharma’s advertising path.

How “patient influencers” look beyond price to help the industry evaluate newly-launched brands.

A description of the changing role of the medical affairs function in pharmaceutical companies and the subsequent evolution to a never ending measurement of the output of medical affairs. How to overcome this quest for sometimes meaningless numbers to justify its existence.

There is a real opportunity for pharma to support the under-served population of atopic dermatitis patients, writes Mariel Metcalfe.

And ways pharma can help overcome these hurdles-and boost compliance rates across the full durations of treatment

Pharm Exec chronicles the military-industry effort to instill the principles of adaptive leadership into today’s pharma leader-a C-suite must in reviving the industry’s beleaguered reputation.

Program puts a new-and very real-spin on patient nutrition.

FDA's approval of the first-ever digital medicine, while sparking legitimate concerns around ethics and trust, could signal improvements ahead to the much-chronicled woes in drug adherence and compliance.

This article explores the difficult nature of developing drugs for rare diseases and discusses what a pharmaceutical executive can actively do to help increase success.

Mary Lynne Hedley, president and COO of TESARO, talks to Pharm Exec about the company’s innovative approach to responsible drug development and commercialization, and how its theory of putting patients first is translated into practise.

Funso Olufade discusses how solutions such as the new Adherence Package can help increase pharma–patient engagement.

Q&A spotlights the development of one injection device that is helping change the treatment-adherence landscape.

How companies are closing the innovation gap between the lab and the patient, while also creating value for all stakeholders.

Here's to hoping that PhRMA's new public education campaign advances the voice of the patient in its messaging.

How can Pharma balance the need to access to patient data and still respect patient privacy? One approach is to access patients through third-party online communities, writes Peter Houston.

Balancing today’s health data demands and patient privacy is not about new regulations-it’s taking a risk-based approach.

Amid today's growing constituency of cancer survivors, oncology is testing the historic divide in medicine between what’s science and what’s social.

Pharma's challenge is to break the cycle of mistrust so that its pioneering work can fully reach patients in need, writes GSK's Murray Stewart.

For those willing to invest in the right capabilities, offering patient services can give pharma companies a tremendous opportunity.